Breast cancer cell–derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and antitumor function

• DOI: 10.1172/jci157248
• Publication Date: 2022-08-04T16:00:35Z
• Authors: Junfeng Wang; Quanyi Wang; Yinan Guan; Yulu Sun; Xiaozhi Wang; Kaylie Lively; Yuzhen Wang; Ming Luo; Julian A. Kim; E. Angela Murphy; Yongzhong Yao; Guoshuai Cai; Daping Fan
• Keywords: miR-155; Tumor progression; Immune checkpoint

Evidence suggests that increased microRNA-155 (miR-155) expression in immune cells enhances antitumor responses. However, given the reported association of miR-155 with tumorigenesis various cancers, a debate is provoked on whether oncogenic or tumor suppressive. We aimed to interrogate impact expression, particularly cancer cell-derived miR-155, immunity breast cancer. performed bioinformatic analysis human databases, murine experiments, and specimen examination. revealed higher levels correlate favorable profile better patient outcomes. Murine experiments demonstrated overexpression enhanced T cell influx, delayed growth, sensitized tumors checkpoint blockade (ICB) therapy. Mechanistically, upregulated their CXCL9/10/11 production, which was mediated by SOCS1 inhibition phosphorylated STAT1 (p-STAT1)/p-STAT3 ratios. further found serum patients correlated status. Our findings suggest high may be prognostic marker for therapeutic elevation improve efficacy ICB therapy via remodeling landscape.